Search Count: 5
 |
Identification Of The Clinical Development Candidate Mrtx849, A Covalent Krasg12C Inhibitor For The Treatment Of Cancer
Organism: Homo sapiens
Method: X-RAY DIFFRACTION Resolution:2.27 Å Release Date: 2020-04-22 Classification: HYDROLASE/INHIBITOR Ligands: GDP, MG, M1R |
 |
Identification Of The Clinical Development Candidate Mrtx849, A Covalent Krasg12C Inhibitor For The Treatment Of Cancer
Organism: Homo sapiens
Method: X-RAY DIFFRACTION Resolution:2.03 Å Release Date: 2020-04-22 Classification: HYDROLASE/INHIBITOR Ligands: GDP, MG, QH4 |
 |
Identification Of The Clinical Development Candidate Mrtx849, A Covalent Krasg12C Inhibitor For The Treatment Of Cancer
Organism: Homo sapiens
Method: X-RAY DIFFRACTION Resolution:1.94 Å Release Date: 2020-04-22 Classification: HYDROLASE/INHIBITOR Ligands: GDP, MG, M1X |
 |
Organism: Homo sapiens
Method: X-RAY DIFFRACTION Resolution:1.80 Å Release Date: 2018-12-12 Classification: ONCOPROTEIN Ligands: GDP, MG, K9M |
 |
Organism: Homo sapiens
Method: X-RAY DIFFRACTION Resolution:1.72 Å Release Date: 2018-12-12 Classification: ONCOPROTEIN Ligands: GDP, MG, K9J |